💬In plain words
What the trial is, and whether it could suit you
The late-stage forms of degenerative osteoarthritis (OA) are very debilitating and less affordable to therapy. The main objective is to identify early onset symptoms of hand OA patients through imaging techniques (such as ultrasound and MRI). Our primary endpoint is to specify patients with high risk of radiological profression (X-ray).
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
\- Early digital osteoarthritis must combine the clinical AND radiological definition.
Clinical definition:
At least one of the following 4 criteria: Pain or stiffness or swelling or deformity of a digital joint (IPP and / or IPD) A breach of at least one PPI and / or IPD Age under 60 at the time of the first symptoms Clinical symptoms have been changing for less than 3 years
Radiographic definition:
The presence of the achievement of at least one PPI and / or IPD. Presence of at least two of the following three criteria: pinching, marginal subchondral condensation, marginal osteophyte Erosion on radiography is not an exclusion criteria
\- Consent form signed
Exclusion criteria:
* patients suffering from rheumatoid arthritis, rheumatoid psoriasis or any other inflammatory rheumatism
* patients suffering from metabolic diseasis such as gout, hemochromatosis, Wilson's disease; or from congenital disease such as displasie, osteogenesis,
* Presence of advanced radiographic osteoarthritis based in Kellgreen Lawrence score (=4) in one joint among the 10 previous sites.
* Not able to provide a sample of blood for any reasons
* MRI contraindication
* Being in exclusion period determined by another previous study
* Subject non affiliated to social insurance
* Pregnant or lactating women
* Vulnerable people based in L1121-5 article of CSP
* Elderly subject or protected subjects disabled to give their consent
* Subjects private of freedom by court or administrative order
💊
What it tests
- Identification of subgroups of patients with early AD with risk of progression
Department of Rheumatology, CHU Montpellier
Montpellier, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky